findmyKOL
Clinical trialNCT06097728Active, not recruitingPhase 3Interventional

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

SponsorAstraZenecaEnrollment861Unresectable Pleural Mesothelioma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

151 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Research Site

    Chermside, Australia

  • Research Site

    Clayton, Australia

  • Research Site

    Melbourne, Australia

  • Research Site

    Nedlands, Australia

  • Research Site

    Westmead, Australia

Belgium
  • Research Site

    Anderlecht, Belgium

  • Research Site

    Antwerp, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Hasselt, Belgium

  • Research Site

    Sint-Niklaas, Belgium

Brazil
  • Research Site

    Barretos, Brazil

  • Research Site

    Fortaleza, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Santo André, Brazil

  • Research Site

    São Paulo, Brazil

Canada
  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

China
  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Guangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Harbin, China

  • Research Site

    Kunming, China

  • Research Site

    Lanzhou, China

  • Research Site

    Ningbo, China

  • Research Site

    Qingdao, China

  • Research Site

    Shandong, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenyang, China

  • Research Site

    Taiyuan, China

  • Research Site

    Taiyuan, China

  • Research Site

    Tianjin, China

  • Research Site

    Tianjin, China

  • Research Site

    Wuhan, China

111 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
9 Nov 2023
Primary completion
16 Nov 2028
Completion
16 Nov 2028
Last update posted
9 Jun 2026
Registered enrollment
861
Registry id
NCT06097728

Cross-registrations

EU-CTR / CTIS (EudraCT)2023-000067-32EU-CTR / CTIS (EudraCT)2023-503231-17-00

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.